EW - Edwards Lifesciences Corporation

NYSE - NYSE Delayed Price. Currency in USD
135.95
-1.62 (-1.18%)
At close: 4:01PM EDT

136.12 +0.17 (0.13%)
After hours: 4:23PM EDT

Stock chart is not supported by your current browser
Previous Close137.57
Open137.50
Bid0.00 x 1100
Ask148.50 x 1100
Day's Range135.25 - 137.82
52 Week Range100.20 - 143.22
Volume1,002,330
Avg. Volume1,374,434
Market Cap28.655B
Beta0.70
PE Ratio (TTM)52.33
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Edwards Lifesciences To Present At The Bernstein 34th Annual Strategic Decisions Conference
    PR Newswireyesterday

    Edwards Lifesciences To Present At The Bernstein 34th Annual Strategic Decisions Conference

    IRVINE, Calif. , May 24, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...

  • Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve
    PR Newswire3 days ago

    Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve

    Study comparison shows results of almost 2,000 intermediate-risk patients at more than 450 U.S. centers PARIS , May 22, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader ...

  • Edwards Announces Key Events For EuroPCR 2018
    PR Newswire5 days ago

    Edwards Announces Key Events For EuroPCR 2018

    PARIS , May 21, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced ...

  • Edwards Lifesciences To Webcast Annual Meeting Of Stockholders
    PR Newswire11 days ago

    Edwards Lifesciences To Webcast Annual Meeting Of Stockholders

    IRVINE, Calif. , May 14, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will ...

  • ACCESSWIRE18 days ago

    Free Post Earnings Research Report: Edwards Lifesciences’ Adjusted Sales Grew 9.3%; Adjusted EPS Surged 30%

    LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free earnings report on Edwards Lifesciences Corp. (NYSE: EW), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EW. Edwards Lifesciences reported its first quarter fiscal 2018 operating and financial results on April 24, 2018. Additionally, the Company provided guidance for the upcoming quarter and fiscal year.

  • GlobeNewswire19 days ago

    Market Trends Toward New Normal in Anadarko Petroleum, Edwards Lifesciences, American Eagle Outfitters, Express, Norfolk Southern, and Investors Real Estate Trust — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, May 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Anadarko ...

  • Edwards Lifesciences Enters Into Accelerated Share Repurchase Agreement
    PR Newswire25 days ago

    Edwards Lifesciences Enters Into Accelerated Share Repurchase Agreement

    Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring.  Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.Edwards.com and follow us on Twitter @EdwardsLifesci.

  • Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy
    PR Newswire25 days ago

    Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy

    IRVINE, Calif., April 30, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark for the Edwards Cardioband Tricuspid Valve Reconstruction System for the treatment of tricuspid regurgitation. The Cardioband Tricuspid System is the first commercially available transcatheter therapy for the treatment of tricuspid heart valve disease. "Although open-heart surgical valve repair is practiced today, it has not been performed frequently for those suffering from tricuspid regurgitation, despite evidence of increased mortality in these patients," said Prof. Georg Nickenig, chief, Department of Cardiology, University Hospital, Bonn, Germany.

  • Edwards Lifesciences Reports First Quarter Results
    PR Newswirelast month

    Edwards Lifesciences Reports First Quarter Results

    IRVINE, Calif. , April 24, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...

  • ACCESSWIRElast month

    Edwards Lifesciences Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 24, 2018 / Edwards Lifesciences Corporation (NYSE: EW ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 24, 2018 at 5:00 PM Eastern ...

  • Edwards Lifesciences To Host Earnings Conference Call On April 24, 2018
    PR Newswirelast month

    Edwards Lifesciences To Host Earnings Conference Call On April 24, 2018

    IRVINE, Calif. , April 10, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...

  • Edwards Prevails In U.S. Patent Office Review That Finds Boston Scientific Transcatheter Valve Patent Claims Invalid
    PR Newswire2 months ago

    Edwards Prevails In U.S. Patent Office Review That Finds Boston Scientific Transcatheter Valve Patent Claims Invalid

    WASHINGTON, March 23, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the United States Patent and Trademark Office (USPTO) decided in Edwards' favor in an Inter Partes Review (IPR) of Boston Scientific's U.S. transcatheter heart valve patent, number 8,992,608 (the '608 patent).  The USPTO determined that all claims of the '608 patent that have been asserted against Edwards are invalid.

  • Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In Europe
    PR Newswire2 months ago

    Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In Europe

    IRVINE, Calif., March 21, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that enrollment is complete in the computed tomography (CT) imaging sub-study within the PARTNER 3 trial of the SAPIEN 3 valve. This randomized sub-study is examining leaflet mobility of both the SAPIEN 3 valve and surgical heart valves in low-risk patients undergoing valve replacement for the treatment of severe aortic stenosis. Enrollment in the PARTNER 3 main study of the SAPIEN 3 valve in low-risk patients was already complete.

  • Edwards' Acumen Hypotension Prediction Index Launches In The U.S.
    PR Newswire2 months ago

    Edwards' Acumen Hypotension Prediction Index Launches In The U.S.

    IRVINE, Calif., March 19, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the U.S. Food and Drug Administration granted the De Novo request for Edwards' Acumen Hypotension Prediction Index (HPI) software. The company will initiate a targeted launch of this first-of-its-kind technology that leverages predictive analytics to alert clinicians to address potential hypotension, or low blood pressure, before it occurs in their surgical patients. "Even brief periods of hypotension are associated with complications or, worse, death after surgery," said Maxime Cannesson, MD, PhD, Professor and Vice Chair, Department of Anesthesiology and Perioperative Medicine, at UCLA.

  • Edwards Lifesciences To Present At The Cowen 38th Annual Health Care Conference
    PR Newswire3 months ago

    Edwards Lifesciences To Present At The Cowen 38th Annual Health Care Conference

    IRVINE, Calif. , March 6, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...

  • GlobeNewswire3 months ago

    Detailed Research: Economic Perspectives on Yum! Brands, Dr Pepper Snapple Group, The Sherwin-Williams, Edwards Lifesciences, Monsanto, and Baker Hughes — What Drives Growth in Today's Competitive Landscape

    NEW YORK, March 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Edwards' Self-Expanding Transcatheter Heart Valve Receives CE Mark
    PR Newswire3 months ago

    Edwards' Self-Expanding Transcatheter Heart Valve Receives CE Mark

    IRVINE, Calif., Feb. 15, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced it has received CE Mark for its self-expanding CENTERA valve for severe, symptomatic aortic stenosis patients at high risk of open-heart surgery. The Edwards CENTERA valve is repositionable and retrievable and can be delivered through a low-profile, 14-French, motorized delivery system. "With the Edwards CENTERA valve, European clinicians and their patients may now benefit from a self-expanding TAVR option that has demonstrated exceptional clinical safety and performance outcomes in the high surgical risk population," said Didier Tchétché, M.D., of Clinique Pasteur in Toulouse, France.

  • Edwards Lifesciences Reports Fourth Quarter Results
    PR Newswire4 months ago

    Edwards Lifesciences Reports Fourth Quarter Results

    IRVINE, Calif. , Feb. 1, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today ...

  • ACCESSWIRE4 months ago

    Edwards Lifesciences Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 1, 2018 / Edwards Lifesciences Corporation (EXCHANGE: EW ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 1, 2018 at 5:00 ...

  • Edwards Lifesciences To Host Earnings Conference Call On February 1, 2018
    PR Newswire4 months ago

    Edwards Lifesciences To Host Earnings Conference Call On February 1, 2018

    IRVINE, Calif. , Jan. 18, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...

  • Edwards Lifesciences To Present At The 36th Annual J.P. Morgan Healthcare Conference
    PR Newswire5 months ago

    Edwards Lifesciences To Present At The 36th Annual J.P. Morgan Healthcare Conference

    IRVINE, Calif. , Jan. 2, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...

  • Edwards Lifesciences' Board Approves New $1 Billion Share Repurchase Program
    PR Newswire6 months ago

    Edwards Lifesciences' Board Approves New $1 Billion Share Repurchase Program

    Company Also Enters Into Accelerated Share Repurchase Agreement NEW YORK , Dec. 7, 2017 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for ...

  • Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
    PR Newswire6 months ago

    Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference

    NEW YORK , Dec. 7, 2017 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will discuss ...

  • PR Newswire6 months ago

    Edwards Acquires Harpoon Medical

    IRVINE, Calif., Dec. 6, 2017 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced the acquisition of Harpoon Medical, Inc., a privately held medical technology company pioneering beating-heart repair for degenerative mitral regurgitation (DMR).  Edwards announced a structured upfront investment in Harpoon in 2015, with an exclusive option to acquire the company. Under the terms of the merger agreement, Edwards paid $100 million in cash for Harpoon at closing on Dec. 1.  In addition, there is the potential for up to $150 million in pre-specified milestone-driven payments over the next 10 years.